(Q36249975)

13 August 2017

1 reference

title

Alzheimer's disease: the benefits of early treatment (English)

1 reference

13 August 2017

0 references

S G Gauthier

1

1 reference

13 August 2017

publication date

1 October 2005

1 reference

European Journal of Neurology

13 August 2017

published in

1 reference

13 August 2017

volume

12 Suppl 3

1 reference

13 August 2017

page(s)

11-16

1 reference

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Mild cognitive impairment, amnestic type: an epidemiologic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Predictors of institutionalization for people with dementia living at home with a carer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Predictors of cognitive and functional progression in patients with probable Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

Regulatory aspects of vascular dementia in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2005.01322.X

10.1111/J.1468-1331.2005.01322.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference